Archives of Gynecology and Obstetrics

, Volume 299, Issue 6, pp 1737–1746 | Cite as

Blockade pf CD73/adenosine axis improves the therapeutic efficacy of docetaxel in epithelial ovarian cancer

  • Hongmei Li
  • Meihua Lv
  • Baohua Qiao
  • Xia LiEmail author
Images in Obstetrics and Gynecology



Epithelial ovarian cancer (EOC) is the most common and lethal ovarian cancer which threatens women health. Nowadays, the standard treatment is maximal cytoreductive surgical debulking followed by chemotherapy. However, immunosuppressive environment generated by chemotherapy, which can be reversed by immunotherapy, leads to the failure of standard treatment. Therefore, a combination of chemotherapy and immunotherapy will be a promising strategy for EOC patients.


For in vitro study, CD73 expression, CD73 activity, and CD8+ T-cell proliferation were measured after docetaxel (DTXL) treatment with or without CD73 antibody. For in vivo study, tumor growth, tumor weight, and the population of various immune cells in the tumor were analyzed in different drug treatment groups.


DTXL can increase both the CD73 expression and enzymatic activity in patient-derived epithelial cell and ID8 cell while causing immunosuppressive response which was reversed by anti-CD73 antibody (aCD73). Moreover, tumor growth and lung metastasis in mouse were significantly diminished after DTXL + aCD73 treatment.


Blocking CD73/adenosine pathway could reverse the immunosuppression caused by DTXL, and a combination of DTXL with CD73 inhibitor or anti-CD73 antibody would be a more effective and promising therapy for EOC.


Epithelial ovarian cancer Docetaxel CD73 Chemotherapy Patient-derived cancer cell 


Author contributions

Data collection and analysis: HL, ML, BQ, and XL; study designed and manuscript writing: XL. All authors approved the final submission.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest to disclose.

Research involving human participants and/or animals

Human study was approved by the Ethical Committee in Heze Municipal Hospital of Shandong Province. All animal studies were in accordance with Guide for the Care and Use of Laboratory Animals (8th edition, NIH), and approved by the Institutional Animal Care and Use Committee in Heze Municipal Hospital of Shandong Province.

Informed consent

Written consent was derived from the participants.


  1. 1.
    Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7–30. CrossRefGoogle Scholar
  2. 2.
    Reid BM, Permuth JB, Sellers TA (2017) Epidemiology of ovarian cancer: a review. Cancer Biol Med 14(1):9–32. CrossRefGoogle Scholar
  3. 3.
    Desai A, Xu J, Aysola K, Qin Y, Okoli C, Hariprasad R, Chinemerem U, Gates C, Reddy A, Danner O, Franklin G, Ngozi A, Cantuaria G, Singh K, Grizzle W, Landen C, Partridge EE, Rice VM, Reddy ES, Rao VN (2014) Epithelial ovarian cancer: an overview. World J Transl Med 3(1):1–8. CrossRefGoogle Scholar
  4. 4.
    Guppy AE, Nathan PD, Rustin GJ (2005) Epithelial ovarian cancer: a review of current management. Clin Oncol (Royal College of Radiologists (Great Britain)) 17(6):399–411CrossRefGoogle Scholar
  5. 5.
    Coward JI, Middleton K, Murphy F (2015) New perspectives on targeted therapy in ovarian cancer. Int J Womens Health 7:189–203. CrossRefGoogle Scholar
  6. 6.
    Kim A, Ueda Y, Naka T, Enomoto T (2012) Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res CR 31:14. CrossRefGoogle Scholar
  7. 7.
    Mittica G, Genta S, Aglietta M, Valabrega G (2016) Immune checkpoint inhibitors: a new opportunity in the treatment of ovarian cancer? Int J Mol Sci. Google Scholar
  8. 8.
    Piccart MJ, Gore M, Ten Bokkel Huinink W, Van Oosterom A, Verweij J, Wanders J, Franklin H, Bayssas M, Kaye S (1995) Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 87(9):676–681CrossRefGoogle Scholar
  9. 9.
    Cristea M, Han E, Salmon L, Morgan RJ (2010) Practical considerations in ovarian cancer chemotherapy. Ther Adv Med Oncol 2(3):175–187. CrossRefGoogle Scholar
  10. 10.
    Katsumata N (2003) Docetaxel: an alternative taxane in ovarian cancer. Br J Cancer 89(Suppl 3):S9–s15. CrossRefGoogle Scholar
  11. 11.
    Yvon AM, Wadsworth P, Jordan MA (1999) Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 10(4):947–959. CrossRefGoogle Scholar
  12. 12.
    Lyseng-Williamson KA, Fenton C (2005) Docetaxel: a review of its use in metastatic breast cancer. Drugs 65(17):2513–2531. CrossRefGoogle Scholar
  13. 13.
    Wellenstein MD, de Visser KE (2018) Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape. Immunity 48(3):399–416. CrossRefGoogle Scholar
  14. 14.
    Anderson KG, Stromnes IM, Greenberg PD (2017) Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell 31(3):311–325. CrossRefGoogle Scholar
  15. 15.
    Guo Z, Wang X, Cheng D, Xia Z, Luan M, Zhang S (2014) PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. PLoS ONE 9(2):e89350. CrossRefGoogle Scholar
  16. 16.
    Mantia-Smaldone GM, Corr B, Chu CS (2012) Immunotherapy in ovarian cancer. Hum Vaccines Immunother 8(9):1179–1191. CrossRefGoogle Scholar
  17. 17.
    Rodriguez GM, Galpin KJC, McCloskey CW, Vanderhyden BC (2018) The tumor microenvironment of epithelial ovarian cancer and its influence on response to immunotherapy. Cancers. Google Scholar
  18. 18.
    Antonioli L, Blandizzi C, Malavasi F, Ferrari D, Hasko G (2016) Anti-CD73 immunotherapy: a viable way to reprogram the tumor microenvironment. Oncoimmunology 5(9):e1216292. CrossRefGoogle Scholar
  19. 19.
    Leone RD, Emens LA (2018) Targeting adenosine for cancer immunotherapy. J Immunother Cancer 6(1):57. CrossRefGoogle Scholar
  20. 20.
    Zhang B (2010) CD73: a novel target for cancer immunotherapy. Can Res 70(16):6407–6411. CrossRefGoogle Scholar
  21. 21.
    Young A, Ngiow SF, Barkauskas DS, Sult E, Hay C, Blake SJ, Huang Q, Liu J, Takeda K, Teng MWL, Sachsenmeier K, Smyth MJ (2016) Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses. Cancer Cell 30(3):391–403. CrossRefGoogle Scholar
  22. 22.
    Jin D, Fan J, Wang L, Thompson LF, Liu A, Daniel BJ, Shin T, Curiel TJ, Zhang B (2010) CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Can Res 70(6):2245–2255. CrossRefGoogle Scholar
  23. 23.
    Theriault BL, Portelance L, Mes-Masson AM, Nachtigal MW (2013) Establishment of primary cultures from ovarian tumor tissue and ascites fluid. Methods Mol Biol (Clifton, NJ) 1049:323–336. CrossRefGoogle Scholar
  24. 24.
    Yao YD, Sun TM, Huang SY, Dou S, Lin L, Chen JN, Ruan JB, Mao CQ, Yu FY, Zeng MS, Zang JY, Liu Q, Su FX, Zhang P, Lieberman J, Wang J, Song E (2012) Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis. Sci Transl Med 4(130):130ra148. CrossRefGoogle Scholar
  25. 25.
    Su F, Kozak KR, Imaizumi S, Gao F, Amneus MW, Grijalva V, Ng C, Wagner A, Hough G, Farias-Eisner G, Anantharamaiah GM, Van Lenten BJ, Navab M, Fogelman AM, Reddy ST, Farias-Eisner R (2010) Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci USA 107(46):19997–20002. CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyHeze Municipal Hospital of Shandong ProvinceHezeChina
  2. 2.Department of HealthHeze Municipal Hospital of Shandong ProvinceHezeChina
  3. 3.Department of GynaecologyHeze Municipal Hospital of Shandong ProvinceHezeChina

Personalised recommendations